uniQure (NASDAQ:QURE) Receives $40.00 Consensus Price Target from Brokerages

uniQure (NASDAQ:QURE) has received a consensus rating of “Buy” from the ten ratings firms that are covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation, six have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month target price among brokers that have covered the stock in the last year is $40.00.

Several brokerages recently commented on QURE. Mizuho upped their price target on shares of uniQure from $7.00 to $20.00 and gave the company a “neutral” rating in a report on Thursday, December 19th. HC Wainwright upped their target price on uniQure from $25.00 to $70.00 and gave the company a “buy” rating in a research note on Monday, January 27th. Royal Bank of Canada reissued an “outperform” rating and set a $24.00 price target on shares of uniQure in a research note on Tuesday, January 21st. Wells Fargo & Company raised uniQure from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, December 10th. Finally, Raymond James upgraded uniQure from an “outperform” rating to a “strong-buy” rating and lifted their target price for the stock from $20.00 to $52.00 in a research report on Tuesday, December 10th.

Insiders Place Their Bets

In other uniQure news, CEO Matthew C. Kapusta sold 3,418 shares of the stock in a transaction on Monday, December 9th. The stock was sold at an average price of $7.63, for a total transaction of $26,079.34. Following the sale, the chief executive officer now owns 597,915 shares of the company’s stock, valued at approximately $4,562,091.45. This trade represents a 0.57 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 4.74% of the stock is owned by company insiders.

Institutional Investors Weigh In On uniQure

Hedge funds have recently made changes to their positions in the stock. Raymond James Financial Inc. purchased a new stake in shares of uniQure during the fourth quarter valued at about $1,951,000. Oppenheimer & Co. Inc. purchased a new stake in uniQure during the fourth quarter valued at approximately $320,000. Palumbo Wealth Management LLC acquired a new stake in uniQure in the fourth quarter valued at approximately $437,000. China Universal Asset Management Co. Ltd. grew its holdings in uniQure by 9.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,062 shares of the biotechnology company’s stock worth $195,000 after purchasing an additional 969 shares during the last quarter. Finally, Sanders Morris Harris LLC increased its position in shares of uniQure by 50.0% during the fourth quarter. Sanders Morris Harris LLC now owns 102,104 shares of the biotechnology company’s stock worth $1,803,000 after purchasing an additional 34,034 shares in the last quarter. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

uniQure Trading Down 9.7 %

QURE stock opened at $14.63 on Monday. uniQure has a twelve month low of $3.73 and a twelve month high of $19.18. The stock has a market capitalization of $713.07 million, a price-to-earnings ratio of -2.95 and a beta of 0.38. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. The firm’s fifty day simple moving average is $14.87 and its two-hundred day simple moving average is $9.25.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.